InvestSMART

Mayne Pharma Group Limited (ASX:MYX)

ALERT: Price-sensitive ASX Announcement for MYX
Current share price for MYX : $2.390 -0.73 (-23.40%)+
Announcement
Release
22 Dec 2025 8:44AM
Price at Release
$3.120
Full Release
download
Summary
Mayne Pharma Group Limited provided a market update for the first five months of FY26, noting a challenging period with mixed results across its segments. The company's total net revenues decreased by 5.5% to $165 million compared to the prior corresponding period. While Women's Health remained flat, the Dermatology sector faced a 12% decline due to increased competition and loss of coverage for certain products. However, significant growth was observed in Women's Health prescriptions, with notable increases for products such as NEXTSTELLIS®, BIJUVA®, and IMVEXXY®. The company also highlighted the successful PBS listing of NEXTSTELLIS® in Australia, enhancing its market potential. Cash and marketable securities stood at $83 million after significant investments and legal expenses. Mayne Pharma remains committed to maximizing shareholder value amidst evolving market conditions.
Key Points
  • Women's Health prescription volumes show strong growth in the first five months of FY26.
  • Dermatology segment experiences a decline due to competition and loss of product coverage.
  • Net revenues for Mayne Pharma are down 5.5% compared to the prior corresponding period.
  • Successful PBS listing for NEXTSTELLIS® in Australia enhances market potential.
  • Cash reserves are at $83 million after key investments and legal expenses.
  • Mayne Pharma continues to focus on maximizing shareholder value amidst market changes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.